Navigation Links
Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
Date:11/29/2007

r cell-destroying, T- cells against tumor cells, and may represent a new therapeutic approach to cancer therapy. BiTE molecules are part of a novel class of antibody derivatives with the potential to selectively direct and activate an individual's cytotoxic T-cells, the body's most potent killer cells, to act against cancer cells. BiTE antibodies have been shown to induce an immunological synapse between a T-cell and a tumor cell in the same manner as observed during physiological T-cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T-cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as "apoptosis," or programmed cell death. In the presence of BiTE antibodies, T-cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at low concentrations and at low ratios of T-cells to target tumor cells. Through the process of killing cancer cells, T-cells proliferate, which leads to an increased number of T-cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE product development platform. In addition to current studies of MT103, three other BiTE antibodies, targeting EpCAM (CD326), CEA and MCSP, are in pre-clinical development.

BiTE is a registered trademark of Micromet.

About MT103

MT103, which is being co-developed with MedImmune as MEDI-538, is a BiTE antibody being developed with the intent to treat certain types of B-cell lymphomas. In February 2006, the U.S. Food and Drug Administration approved an orphan drug designation for MT103 for certain indolent B-cell lymphoma, excluding chronic lymphocytic leukemia and NHL with central nervous system involvement. MT103 also received orphan drug designation from the European Agency for the Evaluation of Medicinal Products for MCL and chronic lymphocytic leukemia
'/>"/>

SOURCE Micromet, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... FL. (PRWEB) , ... August 28, 2015 , ... ... for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on ... that it should begin with the employer and employees getting together for meaningful ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s ... to Work in Healthcare by Modern Healthcare and will be honored at an ... its eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business ... veterans leading in business. Mr. Troy Mizell, Chairman of the Board at ... Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through their ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... a three-year accreditation for its adolescent residential, counseling, day treatment and intensive family ... it meets international standards for quality and its pursuit of excellence. As a ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., ... resulting in shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and ... the University of Illinois, and then went on to earn his title of Doctor ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3
... Two studies that offer new insights to help ... be presented by researchers from Cincinnati Childrens Hospital Medical ... Academic Society (PAS) in Honolulu, Hawaii. , One study, ... asthma dramatically overestimate their ability to control the condition, ...
... Misys plc (FTSE: MSY.L), the,global application software and services ... solutions have been selected by Masraf Al,Rayan to build ... Misys was chosen as the best partner for ... of its proven expertise in Islamic,finance and credibility in ...
... clipping a,pet parrots wings so that it can,t fly in ... pet birds then many people realize, and be,a violation of ... psychological problems as a,direct result from having their God given ... This lack of physical ability to fly and exercise ...
... Integrium, LLC(R), a,cardiovascular and metabolic focused clinical ... results, has officially launched,Integrium Clinical Excellence (ICE), a ... results on time and on,budget in all of ... is a,series of steps that provide a high ...
... 10 Percent Cuts from Taking,Effect July 1; Providers Say ... Calif., May 5 In an effort to,ensure that ... a coalition of health care providers today filed a ... 10 percent cut in,Medi-Cal and Denti-Cal payments from taking ...
... Natural Nutrition,Inc. (OTC Bulletin Board: NTNI) announced today that ... 2008 at 9 PM ET to discuss the upcoming ... iNutrition CEO Tim Connolly said, "iNutrition.com is all ... the very latest sports,lifestyle, and nutrition secrets for a ...
Cached Medicine News:Health News:Teens think they have asthma under control, but benefit from new approach to treatment 2Health News:Misys Facilitates Masraf Al Rayan's Expansion of Islamic Banking Operations 2Health News:Misys Facilitates Masraf Al Rayan's Expansion of Islamic Banking Operations 3Health News:How Clipping Pet Parrot's Wings May Violate Their Animal Rights 2Health News:Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials 2Health News:Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials 3Health News:Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials 4Health News:Health Care Providers Sue State of California Over Cuts in Medi-Cal Payments 2Health News:Health Care Providers Sue State of California Over Cuts in Medi-Cal Payments 3Health News:Health Care Providers Sue State of California Over Cuts in Medi-Cal Payments 4Health News:Health Care Providers Sue State of California Over Cuts in Medi-Cal Payments 5Health News:Natural Nutrition to Hold Conference Call on Launch of iNutrition.com 2
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... with no dose-limiting toxicities - - ... Halozyme to seek input from regulatory authorities in order to ... into pivotal clinical program ... Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing ...
... the identification of,the gene responsible for progeria, a ... of Spanish and French researchers (Carlos,Lopez-Otin and coll. ... and coll. -,Inserm/AP-HM, Marseille, France) have successfully demonstrated ... combining two existing,pharmacological molecules, should slow down the ...
Cached Medicine Technology:Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 2Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 3Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 4Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 5Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
Medicine Products: